An expert discusses how health plans must defend all formulary decisions with clinical evidence and use NCCN/AUA guidelines to create treatment pathways rather than traditional tier placements, with ...
Extreme heat is no longer simply a seasonal weather event. It is becoming an increasingly important population health challenge, with measurable effects on healthcare utilization, costs, and the ...
Reimagine Care is using its own nurses and technology to help community oncology practices build programs for complex cancer therapies such as CAR-T and grow them without hiring n ...
Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier ...
The newest wave of cancer therapies, including CAR-T cell therapy, bispecific antibodies and antibody-drug conjugates, is ...
Lean MASLD/MASH comprises a meaningful subset of patients, with lean MASH linked to higher all-cause mortality and liver events despite lower cardiometabolic comorbidity than obese disease. Adding ...
A post-2018 16.8% rise in Hispanic HIV incidence in anti-sanctuary counties temporally aligned with public charge expansion to Medicaid, consistent with deterrence from prevention, testing, and ...
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew ...
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results